LAUSR.org creates dashboard-style pages of related content for over 1.5 million academic articles. Sign Up to like articles & get recommendations!

Targeted Degradation of KRASG12D as Potential Therapy in Cancer.

Photo from wikipedia

Selective proteolysis represents a cutting-edge therapeutic approach that is garnering global interest due to its capacity to eradicate pathogenic biomolecules within cellular environments. For instance, the PROTAC technology brings the… Click to show full abstract

Selective proteolysis represents a cutting-edge therapeutic approach that is garnering global interest due to its capacity to eradicate pathogenic biomolecules within cellular environments. For instance, the PROTAC technology brings the ubiquitin proteasome system degradation machinery in close proximity of the KRASG12D mutant protein for initiating its degradation and the clearing of abnormal protein debris with unparallel precision, which provides an edge over traditional protein inhibition. This Patent Highlight provides exemplary PROTAC compounds having activity as inhibitors or degraders of the G12D mutant KRAS protein.

Keywords: potential therapy; therapy cancer; krasg12d potential; targeted degradation; degradation krasg12d; degradation

Journal Title: ACS medicinal chemistry letters
Year Published: 2023

Link to full text (if available)


Share on Social Media:                               Sign Up to like & get
recommendations!

Related content

More Information              News              Social Media              Video              Recommended



                Click one of the above tabs to view related content.